- Home
- Companies
- switzerland
- disease modeling
Show results for
Refine by
Disease Modeling Suppliers Serving Switzerland
66 companies found
based inBerlin, GERMANY
PhenoSys was founded in 2006 and is an R&D company based in the centre of Berlin in Germany. We engineer and market innovative technology for animal behaviour research. Our team draws on extensive expertise of electrical and mechanical engineering, ...
The optomotor response (OMR) is a reflex used to assess visual function. The PhenoSys qOMR (quantitative optomotor response) is a unique system that automatically measures the OMR with minimal experimenter effort. It uses a virtual stimulation ...
based inCambridge, UNITED KINGDOM
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and ...
based inAustin, TEXAS (USA)
vivoVerse, Inc., formerly operating as Newormics LLC, develops and manufactures advanced microfluidics, automation, and AI/ML technologies to rapidly and ethically test toxicology/safety profiles of chemicals using C. elegans as a New Approach ...
Our large-scale microfluidic chip for high-throughput screening of C. elegans disease models at high-content, is published in Nature Communications (DOI 10.1038/ncomms13023). The platform enables high-resolution ...
based inEnschede, NETHERLANDS
Micronit is a trusted leader in high-quality microfluidic solutions. Our specialized team empowers clients to bring innovative products to market in life science and healthcare with cutting-edge technology and personalized support. While the world ...
based inBentley DC, AUSTRALIA
Ozgene is one of the leading companies providing genetically modified mice for researchers around the world. We offer a full spectrum of pre-clinical capabilities from the development of mouse models through to breeding, characterisation and ...
Knockout mice are animal models that have been genetically modified to delete or inactivate a specific gene. The term ‘knockout’ refers to knocking out the functionality of the target gene. These mouse ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
BDM-I: Addressing market need for next-generation antimicrobials. Infectious diseases often dominate the media headlines, including rising antibiotic resistance and fear of “super bugs”. One serious problem facing the global community is ...
based inTel Aviv, ISRAEL
The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What’s needed is a technology capable of digesting, organizing and making sense of ...
The first model to map and compare treatments, patient groups and disease mechanisms. ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
GastroPlus is a simulation software designed for detailed mechanistic modeling of drug absorption across various administration routes including intravenous, oral, ocular, inhalation, dermal, subcutaneous, and intramuscular ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Identify the biomarkers best suited for your needs: Diagnose rare or ambiguous diseases, Group patients by endotype response for prognosis, Assess disease etiology to determine responsive patient group ...
based inMunich, GERMANY
The technological progress made in biomedical research has radically changed the view to new treatment strategies. Modern genetic technologies can deliver disease-relevant targets but are insufficient to refill the empty drug discovery pipeline. We ...
The DiseasePROFILER uses a subset of top-performing sensors identified in the PathwayPROFILER assay and enables simple, robust, and cost-effective screening of compound effects in human disease models. ...
based inMadison, WISCONSIN (USA)
InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process by introducing patient-derived and gene-edited human samples, including 3D engineered microtissues. Our unique integration of cell & tissue ...
Human engineered tissue (EHT)-based high content analysis can be applied to drug discovery projects at their compound screening and lead optimization stage. Mass-produced human engineered tissues will recapitulate physiological functions of native ...
based inHuangpu District, CHINA
Moon (Guangzhou) Biotech Co., Ltd., with the title of National High-tech Enterprise, is an innovative biotechnology company focusing on the development and commercialization of microbial products and solutions. With a dedication to discover, ...
From tremendous microbiome resources to precision microbe-based drug. Human microbiome is recognized as the central hub of human health and disease development and harbors tremendous microbe-based drugs for improving human health and treating ...
based inSan Francisco, CALIFORNIA (USA)
Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our ...
Cardiomyocytes are cardiac muscle cells. They are terminally differentiated and facilitate contractile forces (“beatings”) of the heart. Grown in vitro as a monolayer sheath, cardiomyocytes are connected by gap junction proteins ...
based inLa Jolla, California, CALIFORNIA (USA)
AAA Biotech’s antibodies are highly validated and can be used in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. We have antibodies available for rare species and in multiple conjugated forms, in addition to an extensive ...
based inKrakow, POLAND
We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. We have ...
Having experience in both pharma and biotech R&D, we are well aware of what it means to discover a hit and transform it into a drug. You can best benefit from this “insider” experience through our integrated drug discovery services ...
based inNashville, TENNESSEE (USA)
Aspect Imaging Ltd is a global leader in the design and development of compact MR imaging solutions for preclinical and medical applications. The company’s breakthrough technology and related IP –compact high-performance permanent magnets –is the ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to ...
based inRostock, GERMANY
Since 2006, CENTOGENE has helped physicians diagnose thousands of rare disease patients around the world. A quick and accurate diagnosis can end an odyssey of medical tests and visits to multiple medical specialists. It also helps physicians better ...
We work with partners to develop new disease models and new biomarkers of disease. We can also use our disease models to identify new drug targets and screen ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro retinal disease modelling for retinal therapy. Newcells offers a fast and reliable in vitro safety and efficacy service for the evaluation of novel compounds for retinal therapy using complex human retinal ...
based inSeattle, WASHINGTON (USA)
Curi Bio is integrating human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics to accelerate the discovery of new therapeutics. Curi Bio is accelerating the discovery of the next generation of medicines by integrating ...
Mantarray is Curi’s Platform for Human-Relevant 3D Engineered Muscle Tissue Analysis. Get Clinically-relevant Functional Data with 3D Tissues. Mantarray brings functional data into the earliest stages of preclinical testing of new medicines. ...